Amplimmune, GSK in AMP-224 deal

Amplimmune Inc. (Rockville, Md.) granted GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) exclusive, worldwide rights to AMP-224 and other next-generation fusion proteins targeting PD-1 receptor ( PDCD1; PD-1;...